JAKARTA (TheInsiderStories) - National pharmaceutical company, PT Phapros Tbk, a subsidiary of state owned PT Rajawali Nusantara Indonesia, has set a target to book sales of up to Rp 1 trillion this year, up 22% from last year.
“This year, we are targeting sales of Rp 1 trillion,” said President Director of PT Phapros Barokah Sri Utami in a statement received in Jakarta, Wednesday (Mar 15).
To achieve the target, Phapros will launch some corporate actions, such as releasing 8-10 new products, both generic and ethical drugs, throughout 2017.
As for generic drugs, Phapros is projecting sales growth of 46% this year or Rp 580 billion of total sales target of Rp 1 trillion. The company has set capital expenditure (capex) of Rp 290 billion. Some of these funds will be used to increase production capacity, including its a new plant in Ungaran, Semarang,” Sri Utami said.
Sri Utami said, in 2016, the company has recorded sales of Rp816 billion in 2016, up 185 from Rp 691 billion in 2015. The sales rise has also boosted its bottomline. In the year, the company posted net profit of Rp87 billion, up 38% from 2015 of Rp63 billion.
Sri Utami said the net profit growth was “well above” the average growth of the national pharmaceutical industry, which is only about 4.6 percent.
“Of the total sales in 2016, the contribution of generic drugs reached Rp 396.5 billion, or about 49% of total sales,” Sri Utami said.
Meanwhile, the ethical drugs contributed about 25% to the total sales, while OTC (over-the-counter) or non-prescription drugs sales contributed 15% to total sales. Phapros assets in 2016 increased to Rp883 billion from Rp 680 billion in previous year. (HS)